Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant

29Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. Objectives: To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. Methods: Activity of FVa variants was studied in vitro using prothrombinase assays with purified components and in FV- and FVIII-deficient plasma using clotting and thrombin generation assays. In vivo bleed reduction after the tail clip was studied in hemophilia A mice. Results and conclusions: FVa mutations included a disulfide bond connecting the A2 and A3 domains and ones that rendered FVa resistant to inactivation by activated protein C (APC). 'superFVa,' a combination of the A2-A3 disulfide (A2-SS-A3) to stabilize FVa and of APC-cleavage site mutations (Arg506/306/679Gln), had enhanced specific activity and complete APC resistance compared with wild-type FVa, FVLeiden(Arg506Gln), or FVaLeiden(A2-SS-A3). Furthermore, superFVa potently increased thrombin generation in vitro in FVIII-deficient plasma. In vivo, superFVa reduced bleeding in FVIII-deficient mice more effectively than wild-type FVa. Low-dose superFVa, but not wild-type FVa, decreased early blood loss during the first 10 min by more than two-fold compared with saline and provided bleed protection for the majority of mice, similar to treatments with FVIII. During the second 10 min after tail cut, superFVa at high dose, but not wild-type FVa, effectively reduced bleeding. These findings suggest that superFVa enhances not only clot formation but also clot stabilization. Thus, superFVa efficiently improved hemostasis in hemophilia in vitro and in vivo and may have potential therapeutic benefits as a novel bypassing agent in hemophilia. © 2013 International Society on Thrombosis and Haemostasis.

References Powered by Scopus

The Calibrated Automated Thrombogram (CAT): A universal routine test for hyper- and hypocoagulability

595Citations
N/AReaders
Get full text

Cofactor proteins in the assembly and expression of blood clotting enzyme complexes

522Citations
N/AReaders
Get full text

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) study

402Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cerebral Cavernous Malformation: From Mechanism to Therapy

100Citations
N/AReaders
Get full text

Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice

55Citations
N/AReaders
Get full text

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

42Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Von Drygalski, A., Cramer, T. J., Bhat, V., Griffin, J. H., Gale, A. J., & Mosnier, L. O. (2014). Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. Journal of Thrombosis and Haemostasis, 12(3), 363–372. https://doi.org/10.1111/jth.12489

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

47%

Researcher 8

47%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 7

35%

Medicine and Dentistry 7

35%

Biochemistry, Genetics and Molecular Bi... 5

25%

Computer Science 1

5%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free
0